Laing Lance G.
Known title: Chief Science OfficerCIK: 0001716041
Associated companies
Transaction History
| CELC | ▲ Buy | Grant | 20,000 | $0 | 8/14/2026 | View on chart |
| CELC | ▲ Buy | Option Exercise | 1,000 | $10K | 6/2/2026 | View on chart |
| CELC | ▲ Buy | Grant | 20,000 | $0 | 8/14/2026 | View on chart |
| CELC | ▲ Buy | Option Exercise | 1,000 | $10K | 6/2/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Celcuity Shares Fall 17% After REVTORPYK Launch and NDA Filing
Celcuity’s stock fell 17.3% after the company announced the launch of its REVTORPYK product in the U.S. and filed a new drug application. The company also said it will present at the European Society for Medical Oncology congress, adding to the mix of upcoming events. With the price near its 14‑day support level of $87.46 and an RSI of 30.1, the move reflects a short‑term reaction to the news rather than a long‑term trend.
Celcuity Shares Fall 17% After REVTORPYK Launch and NDA Filing. Celcuity’s stock fell 17.3% after the company announced the launch of its REVTORPYK product in the U.S. and filed a new drug application. The company also said it will present at the European Society for Medical Oncology congress, adding to the mix of upcoming events. With the price near its 14‑day support level of $87.46 and an RSI of 30.1, the move reflects a short‑term reaction to the news rather than a long‑term trend.